Chief Financial Officer (Interim)
Daniel Geffken, MBA, is a proven leader of life science companies with more than 30 years of experience steering strategy, finance, and operations across all stages of the corporate life cycle. As co-founder and Managing Director of Danforth Advisors, he leads a team of more than 175 consultants in strategic CFO advisory, accounting, and operational support for over 260 active clients, ranging from life science start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and executive-level advisor to numerous companies, including Apellis Pharmaceuticals, Atea Pharmaceuticals, Century Therapeutics, Cidara Therapeutics, Editas Medicine, Homology Medicines, Prilenia Therapeutics, Promedior and ProMIS Neurosciences. Daniel holds a BS from The Wharton School, University of Pennsylvania, and a MBA from Harvard Business School. In its 10-year history, Danforth has worked with more than 650 life science companies, including Moderna, Beam, Apellis, Black Diamond and Locust Walk Acquisition Corp.